Patents by Inventor James Darrow

James Darrow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9177082
    Abstract: Methods for computer aided design (CAD) and corresponding systems and computer-readable mediums. A method includes performing a setup process to instantiate a booklet of CAD drawings. The method includes receiving a user selection of a template from a user. The method includes receiving geometry content information from the user and receiving reference geometry from a user. The method includes creating the booklet of CAD drawings based on the template, geometry content information and reference geometry. A CAD system maintains a CAD drawing booklet, the CAD drawing booklet associated with a plurality of drawings each including a sheet collection, and each drawing associated with at least one component.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: November 3, 2015
    Assignee: Siemens Product Lifecycle Management Software Inc.
    Inventors: James Darrow Linder, Shrinivas Soman
  • Publication number: 20140351767
    Abstract: Methods for product data management and corresponding systems and computer-readable mediums. A method includes displaying a user interface including at least one target object having a hover area. The method includes detecting that a user-controlled pointer is moved into the hover area and held in place for a first predetermined amount of time. The method includes displaying a dialog associated with the target object in response to the detecting. The method includes receiving configuration data from a user through the dialog and saving the received configuration data. The method can include receiving a selection of an access handle associated with the target object and, in response, activating the access handle and displaying at least one manipulation handle in the user interface.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 27, 2014
    Applicant: SIEMENS PRODUCT LIFECYCLE MANAGEMENT SOFTWARE INC.
    Inventors: James Darrow Linder, Adam Escobedo, Derek Muktarian
  • Publication number: 20130097489
    Abstract: Methods for computer aided design (CAD) and corresponding systems and computer-readable mediums. A method includes performing a setup process to instantiate a booklet of CAD drawings. The method includes receiving a user selection of a template from a user. The method includes receiving geometry content information from the user and receiving reference geometry from a user. The method includes creating the booklet of CAD drawings based on the template, geometry content information and reference geometry. A CAD system maintains a CAD drawing booklet, the CAD drawing booklet associated with a plurality of drawings each including a sheet collection, and each drawing associated with at least one component.
    Type: Application
    Filed: October 14, 2011
    Publication date: April 18, 2013
    Applicant: SIEMENS PRODUCT LIFECYCLE MANAGEMENT SOFTWARE INC.
    Inventors: James Darrow Linder, Shrinivas Soman
  • Publication number: 20070161637
    Abstract: Substituted pyridin-2-ylamine analogues are provided, of the formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
    Type: Application
    Filed: July 22, 2004
    Publication date: July 12, 2007
    Applicant: Neurogen Corporation
    Inventors: Rajagopal Bankthavatchalam, James Darrow, Stephane De Lombaert, Xiaozhang Zheng
  • Publication number: 20060229337
    Abstract: At least one chemical entity chosen from compounds of Formula 2 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    Type: Application
    Filed: March 9, 2006
    Publication date: October 12, 2006
    Inventors: David Brittelli, Kevin Currie, James Darrow, Jeffrey Kropf, Seung Lee, Steven Gallion, Scott Mitchell, Douglas Pippin, Peter Blomgren
  • Publication number: 20060183746
    Abstract: Certain compounds, such as at least one chemical entity choen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, may in certain embodiments be used to treat patients suffering from one or more diseases responsive to inhibition of tyrosine kinase activity. The diseases may, for instance, be responsive to inhibition of Btk activity and/or B-cell proliferation. Example diseases include cancer, an autoimmune and/or inflammatory disease, and an acute inflammatory reaction.
    Type: Application
    Filed: December 2, 2005
    Publication date: August 17, 2006
    Inventors: Kevin Currie, Robert Desimone, Scott Mitchell, Douglas Pippin, James Darrow, Xiaobing Qian, Mark Velleca, Dapeng Qian
  • Publication number: 20060178367
    Abstract: Chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are described herein. Pharmaceutical compositions comprising at least one chemical entity of Formula 1, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell proliferation are described. Methods for determining the presence of Btk in a sample are described.
    Type: Application
    Filed: November 10, 2005
    Publication date: August 10, 2006
    Inventors: Kevin Currie, Jeffrey Kropf, James Darrow, Robert Desimone
  • Publication number: 20060100245
    Abstract: Substituted biphenyl-4-carboxylic acid arylamide analogues capable of modulating receptor activity, are provided. Such ligands may be used to modulate receptor activity in vivo or in vitro, and are particularly useful in the treatment of pain and other conditions associated with receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for receptor localization studies.
    Type: Application
    Filed: December 19, 2003
    Publication date: May 11, 2006
    Applicant: Neurogen Corporation
    Inventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, James Darrow, Stephane DeLombaert, Taeyoung Yoon, Xiaozhang Zheng
  • Publication number: 20060040964
    Abstract: Substituted spiro[isobenzofuran-1,4?-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4?-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.
    Type: Application
    Filed: July 18, 2005
    Publication date: February 23, 2006
    Inventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, James Darrow, Stephane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Elliott, Marlys Hammond
  • Publication number: 20050288295
    Abstract: At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, and prodrugs thereof. Methods of treating or preventing disorders in which aberrant kinase activity is implicated, pharmaceutically compositions, and methods for detecting the presence kinases in cells or biological preparations and for identifying kinases of therapeutic interest.
    Type: Application
    Filed: November 10, 2004
    Publication date: December 29, 2005
    Inventors: Kevin Currie, Robert DeSimone, Douglas Pippin, James Darrow, Scott Mitchell
  • Publication number: 20050090499
    Abstract: Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
    Type: Application
    Filed: June 4, 2004
    Publication date: April 28, 2005
    Inventors: Kevin Currie, Robert DeSimone, Scott Mitchell, Douglas Pippin, James Darrow, Xiaobing Qian, Mark Velleca, Dapeng Qian
  • Publication number: 20050085484
    Abstract: Certain substituted imidazo[1,2-a]pyrazines and the pharmaceutically-acceptable salts thereof, are provided herein. Pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable salt of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Thus methods of treatment include administering a sufficient amount of a compound of the invention to decrease the symptoms or slow the progression of these diseases or disorders.
    Type: Application
    Filed: August 11, 2004
    Publication date: April 21, 2005
    Inventors: Scott Mitchell, Robert DeSimone, James Darrow, Douglas Pippin, M. Danca
  • Publication number: 20050054649
    Abstract: This invention pertains to compounds of Formula I: and the pharmaceutically-acceptable forms thereof. The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and neurodegenerative diseases.
    Type: Application
    Filed: February 10, 2004
    Publication date: March 10, 2005
    Inventors: Kevin Currie, Robert DeSimone, Douglas Pippin, James Darrow, Scott Mitchell
  • Publication number: 20050033048
    Abstract: Substituted spiro[isobenzofuran-1,4?-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4?-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and method for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.
    Type: Application
    Filed: December 11, 2001
    Publication date: February 10, 2005
    Inventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, James Darrow, Stephane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Elliott, Marlys Hammond
  • Publication number: 20030182004
    Abstract: A method of describing products in an electronically-accessible format includes receiving a product geometry description to describe the geometry of a portion of a product, receiving a product attribute description to describe a non-geometric attribute of the portion of the product, and storing the product geometry description and the product attribute description in an electronically-accessible format.
    Type: Application
    Filed: March 22, 2002
    Publication date: September 25, 2003
    Inventors: James Darrow Linder, Xuqiang Wu
  • Publication number: 20030179232
    Abstract: Custom drawing symbols may be created that include geometric data and several notes and different data types for notes. The geometric data may be created using a broad range of features of a computer-aided drawing system. A user interface to create an instance of a custom drawing symbol may be automatically generated. The generated user interface may support a variety of data types for notes, such as integer notes, real number notes, mandatory notes, arbitrary notes, controlled notes, and partially-controlled notes.
    Type: Application
    Filed: March 25, 2002
    Publication date: September 25, 2003
    Inventors: Daniel P. Fousek, Bradley N. Wyckhouse, Betty Sung Huang, James Darrow Linder
  • Publication number: 20010031758
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: April 23, 2001
    Publication date: October 18, 2001
    Applicant: Neurogen Corporation
    Inventors: James Darrow, George Maynard, Raymond Horvath, Jennifer Tran, Stephane De Lombaert